Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0034 | Dantrolene

Molecular Formula C14H10N4O5
Molecular Weight 314.25
Structure
State solid
Protein binding Significant, mostly to albumin.
Half life The mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
Absorption Bioavailability is 70%.
Description hydantoin derivative; postsynaptic muscle relaxant; ryanodine receptor antagonist

M

M03CA01 Dantrolene


[M03CA] Dantrolene and derivatives


[M03C] MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS


[M03] MUSCLE RELAXANTS


[M] Musculoskeletal system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex I activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex IV activity Negative p < 0.05 3
ELECTRON TRANSPORT CHAIN 50 μM bovine heart mitochondria Measurement of complex V activity Negative p < 0.05 3

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 50 μM bovine heart mitochondria Measurement of complex I activity Negative p < 0.05 3
Succinate dehydrogenase 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
Quinol--cytochrome-c reductase 50 μM bovine heart mitochondria Measurement of complex II + III activity Negative p < 0.05 3
Cytochrome c oxidase 50 μM bovine heart mitochondria Measurement of complex IV activity Negative p < 0.05 3
ATP synthase 50 μM bovine heart mitochondria Measurement of complex V activity Negative p < 0.05 3

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 7 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


Reported as not meeting GHS hazard criteria by 1 of 7 companies. For more detailed information, please visit ECHA C&L website


Of the 1 notification(s) provided by 6 of 7 companies with hazard statement code(s):


H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity]


H351 (100%): Suspected of causing cancer [Warning Carcinogenicity]


H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


H373 (100%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P201, P202, P260, P281, P308+P313, P314, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 subcutaneous > 16gm/kg (16000mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
mouse LD50 intraperitoneal 534mg/kg (534mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
rat LD50 intraperitoneal 413mg/kg (413mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
mouse LD50 intravenous > 50mg/kg (50mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
rat LD50 intravenous > 50mg/kg (50mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
rat LD50 subcutaneous > 16gm/kg (16000mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
women LDLo oral 600mg/kg (600mg/kg) New York State Journal of Medicine. Vol. 77, Pg. 1759, 1977.
mouse LD50 intravenous > 7gm/kg (7000mg/kg) Journal of Medicinal Chemistry. Vol. 21, Pg. 127, 1978.
human TDLo oral 320mg/kg (320mg/kg) JAMA, Journal of the American Medical Association. Vol. 231, Pg. 662, 1975.
mouse LD50 oral 1188mg/kg (1188mg/kg) Journal of Pharmaceutical Sciences. Vol. 69, Pg. 327, 1980.
rat LD50 oral 7432mg/kg (7432mg/kg) Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977.
dog LD50 oral > 10550mg/kg (10550mg/kg) Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994.

  • Body temperature increased

  • Carbon dioxide increased

  • Cerebral palsy

  • Cerebrovascular accident

  • Clonus

  • Cyanosis

  • Hypercapnia

  • Hypermetabolism

  • Immobile

  • Metabolic acidosis

  • Multiple sclerosis

  • Muscle rigidity

  • Muscle spasticity

  • Neuroleptic malignant syndrome

  • Spinal cord injury

  • Tachycardia

  • Tachypnoea

  • Asthenia

  • Atrioventricular block

  • Dizziness

  • Dysphagia

  • Dysphonia

  • Feeling abnormal

  • Flushing

  • Headache

  • Infusion site pain

  • Muscular weakness

  • Nausea

  • Pain in extremity

  • Somnolence

  • Tachycardia

  • Vision blurred

  • Vomiting

    • (E)-1-(((5-(4-nitrophenyl)furan-2-yl)methylene)amino)imidazolidine-2,4-dione 1-(((5-(4-Nitrophenyl)-2-furanyl)methylene)amino)-2,4-imidazolidinedione 1-(((E)-[5-(4-Nitrophenyl)-2-furyl]methylidene)amino)-2,4-imidazolidinedione #
    1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin 1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione 1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
    1-[5-(4-nitro-phenyl)-furan-2-ylmethyleneamino]-imidazolidine-2,4-dione 1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-
    2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]- 7261-97-4 833480-90-3
    85008-71-5 A13928 BCBcMAP01_000067
    BDBM50198767 BIDD:GT0187 BPBio1_000246
    BRD-K81272440-001-02-6 BRD-K81272440-236-05-1 BRN 0705189
    BSPBio_000222 BSPBio_001305 BSPBio_003074
    C06939 C14H10N4O5 CHEBI:4317
    CHEMBL1201288 D02347 DB01219
    DTXSID70873546 Dantrium Dantrolene (USAN/INN)
    Dantrolene [USAN:BAN:INN] Dantrolene [USAN:INN:BAN] Dantroleno
    Dantroleno [INN-Spanish] Dantrolenum Dantrolenum [INN-Latin]
    EINECS 230-684-8 F-368 F64QU97QCR
    HMS1361B07 HMS1791B07 HMS1989B07
    HMS3402B07 HSDB 3050 Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-
    IDI1_000898 IDI1_033775 LS-76264
    Lopac0_000424 NCGC00163132-01 NCGC00163402-01
    NCGC00163402-02 NCGC00163402-03 NCGC00188950-01
    OZOMQRBLCMDCEG-VIZOYTHASA-N Prestwick2_000291 Prestwick3_000291
    R452 Ryanodex SCHEMBL12417164
    SCHEMBL40893 SR-01000076241-8 Spectrum5_001752
    UNII-F64QU97QCR ZINC7997966 [4-(5-{(E)-[(2,4-Dioxoimidazolidin-1-yl)imino]methyl}furan-2-yl)phenyl](hydroxy)oxoammonium
    dantrolene

    DrugBank Name Dantrolene
    DrugBank DB01219
    CAS Number 14663-23-1, 7261-97-4, 833480-90-3, 85008-71-5
    PubChem Compound 6914273
    KEGG Compound ID C06939
    KEGG Drug D02347
    PubChem.Substance 46504976
    ChEBI 4317
    PharmGKB PA449208
    ChemSpider 5290202
    BindingDB 50198767.0
    TTD DNC001623
    Wikipedia Dantrolene
    DPD 2402

    1. Dykens et al. (2007)